Blocking Bone Metastases in Prostate Cancer by Using Approved HIV Drugs

Normally I don't write about pre-clinical things unless they are particularly interesting. You guessed it; I found a preclinical item that is interesting. According to a recent published study by Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University the receptor CCR5, which is targeted by already approved HIV drugs that are on the market is also key in the driving of prostate cancer metastases. This suggests that by blocking this receptor we might also slow prostate cancer spread. The study published online in the journal Cancer Research, researchers show that the receptor [...]